Bio-Rad Laboratories, Inc. (BIO) Enterprise Value (EV): $9.26B
The enterprise value (EV) for Bio-Rad Laboratories, Inc. (BIO) is $9.26B as of Wednesday, June 10, 2026.
BIO Enterprise Value (EV) Metrics
ENTERPRISE VALUE (EV)
$9.26B
BIO Competitors' Enterprise Value (EV)
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Bio-Rad Laboratories, Inc. (BIO) | $7.89B | $9.26B |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | $12.95B |
| Hims & Hers Health, Inc. (HIMS) | $6.42B | $8.34B |
| Baxter International Inc. (BAX) | $10.49B | $17.84B |
| Align Technology, Inc. (ALGN) | $12.56B | $10.36B |
| Hologic, Inc. (HOLX) | $16.97B | $15.94B |
| Moderna, Inc. (MRNA) | $18.40B | $10.79B |
| BioNTech SE (BNTX) | $21.81B | $14.31B |
| Mettler-Toledo International Inc. (MTD) | $22.85B | $31.01B |
| Waters Corporation (WAT) | $23.83B | $23.51B |
Enterprise Value Calculation
Market Cap
$7.89B
Total Debt
$1.38B
Cash
$531.80M
Enterprise Value
$9.26B
EV-Based Valuation Multiples
Why use EV instead of Market Cap?
- EV accounts for debt - an acquirer must pay or assume it
- EV deducts cash - the acquirer effectively receives it
- EV enables fair comparison of companies with different capital structures
- EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral
Bio-Rad Laboratories, Inc. Enterprise Value (EV) Formula & Definition
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bio-Rad Laboratories, Inc. Enterprise Value (EV) FAQ
- What is the enterprise value (EV) for Bio-Rad Laboratories, Inc. (BIO)?
- The enterprise value (EV) for BIO stock is $9.26B.
Related Metrics
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz